AnaptysBio, Inc. (NASDAQ:ANAB) Director Buys $842,177.28 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc purchased 65,184 shares of the company’s stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the purchase, the director now owns 7,860,180 shares of the company’s stock, valued at approximately $101,553,525.60. This trade represents a 0.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, January 2nd, Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock. The shares were bought at an average price of $12.95 per share, for a total transaction of $86,065.70.

AnaptysBio Price Performance

Shares of ANAB stock opened at $13.36 on Friday. The firm has a 50-day moving average of $20.10 and a 200-day moving average of $28.50. AnaptysBio, Inc. has a one year low of $12.51 and a one year high of $41.31. The company has a market cap of $406.53 million, a P/E ratio of -2.20 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. As a group, research analysts expect that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. raised its stake in shares of AnaptysBio by 140.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after purchasing an additional 1,265,891 shares during the period. FMR LLC grew its position in AnaptysBio by 15.3% during the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after buying an additional 438,557 shares during the period. Jennison Associates LLC purchased a new stake in AnaptysBio during the third quarter worth about $8,874,000. Victory Capital Management Inc. raised its position in AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in shares of AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after acquiring an additional 168,813 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ANAB. HC Wainwright downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating and decreased their price target for the company from $52.00 to $19.00 in a research note on Wednesday, December 11th. Guggenheim dropped their price target on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Wedbush restated an “outperform” rating and set a $40.00 price objective (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Truist Financial cut their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Finally, BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.45.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.